CLIA Kit for Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1)

27.4-20, 000pg/mL

The minimum detectable dose of this kit is typically less than 12.3pg/mL

2h, 40min

This assay has high sensitivity and excellent specificity for detection of Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1).
No significant cross-reactivity or interference between Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The microplate provided in this kit has been pre-coated with an antibody specific to Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Neuroblastoma, Suppression Of Tumorigenicity 1 (NBL1) level in the sample or standard.;